Colon polyps and cytokines: Emerging immunological mechanisms

Romanian Journal of Gastroenterology

Volumn 12, Issue 3, 2003, Pages 207-214

  Jacobson Brown, Pearl ^a   Neuman, Manuela G ^b,c  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^b Kunin Lunenfeld Applied Research Unit and Department of Food and Nutrition Services and Baycrest Centre for Geriatric Care   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Adenomatous polyps; Apoptosis; Chemokines; Cytokines

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; CYTOKINE; GAMMA INTERFERON; GROWTH FACTOR; INTERLEUKIN 12; INTERLEUKIN 2; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ADENOMA; ANTIGEN RECOGNITION; APOPTOSIS; CANCER MODEL; CELL ADHESION; CELL PROLIFERATION; CELLULAR IMMUNITY; COLON ADENOMA; COLON CANCER; COLON POLYP; COLORECTAL CANCER; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; HELPER CELL; HOST PATHOGEN INTERACTION; HUMAN; IMMUNE RESPONSE; IMMUNITY; MOLECULAR BIOLOGY; PRECANCER; PROGNOSIS; REVIEW; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; TUMOR GROWTH; TUMOR HOST INTERACTION;

ADENOMATOUS POLYPS; COLONIC POLYPS; CYTOKINES; HUMANS; IMMUNITY, CELLULAR;

EID: 0141626913     PISSN: 12214167     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (60)

1. Pignone M, Levin B. Recent developments in colorectal cancer screening and prevention. Am Fam Physician 2002; 66: 297-302.
2. Shirovich BE, Schwartz LM, Woloshin S. Screening men for prostate and colorectal cancer in the United States: Does practice reflect the evidence? JAMA 2003; 289: 1414-1420.
3. Roberts GT, Davies ML, Wakeman JA. Interaction between Ku80 protein and a widely used antibody to adenomatous polyposis coli. Br J Cancer 2003; 88: 202-205.
4. Chen-Shtoyerman R, Theodor L, Harmati E, et al. Genetic analysis of familial colorectal cancer in Israeli Arabs. Hum Mutat 2003; 4: 446-447.
5. Smith, RA et al. American Cancer Society Guidelines for the Early Detection of Cancer: Update of Early Detection Guidelines for Prostate, Colorectal, and Endometrial Cancers. Cancer J Clin 2001; 51: 38-75.
6. Compton CC. Colorectal carcinoma: diagnostic, prognostic, and molecular features. Mod Pathol 2003; 16: 376-388.
7. Adegboyega PA, Mifflin RC, DiMari JF, et al. Immunohistochemical study of myofibroblasts in normal colonic mucosa, hyperplastic polyps, and adenomatous colorectal polyps. Arch Pathol Lab Med 2002; 126: 829-836.
8. Cheng TI, Wong JM, Hong CF, et al. Colorectal cancer screening in asymptomatic adults: comparison of colonoscopy, sigmoidoscopy and fecal occult blood tests. J Formos Med Assoc 2002; 101: 685-690.
9. Peipins LA, Sandler RS. Epidemiology of colorectal adenomas. Epidemiol Rev 1994; 16: 273-297.
10. Konishi K, Kaneko K, Kurahashi T, et al. A comparison of magnifying and nonmagnifying colonoscopy for diagnosis of colorectal polyps: A prospective study. Gastrointest Endosc 2003; 57: 48-53.
11. Dohlsten M, Lando PA, Bjork P, et al. Immunotherapy of human colon cancer by antibody-targeted superantigens. Cancer Immunol Immunother 1995; 41: 162-168.
12. Rosenberg SA. Progress in human tumour immunology and immunotherapy. Nature 2001; 411: 380-384.
13. Makrigiannis AP, Musgrave BL, Mansour H, et al. Interleukin-12 can replace CD28-dependent T-cell costimulation during nonspecific cytotoxic T lymphocyte induction by anti-CD3 antibody. J Leukocyte Biol 2001; 69: 113-122.
14. Maraskovsky E, Chen WF, Shortman K. IL-2 and IFN-gamma are two necessary lymphokines in the development of cytolytic T cells. J Immunol 1989; 143: 1210-1214.
15. Siapati KE, Barker S, Kinnon C, et al. Improved antitumour immunity in murine neuroblastoma using a combination of IL-2 and IL-12. Br J Cancer 2003; 88: 1641-8.
16. Tanaka M, Saijo Y, Sato G, et al. Induction of antitumor immunity by combined immunogene therapy using IL-2 and IL-12 in low antigenic Lewis lung carcinoma. Cancer Gene Ther 2000; 7: 1481-1450.
17. Smyth MJ, Takeda K, Hayakawa Y, et al. Nature's TRAIL-on a path to cancer immunotherapy. Immunity. 2003; 18: 1-6.
18. Ashkenazi A. Targeting death and decoy receptors of the tumournecrosis factor superfamily. Nat Rev Cancer 2002; 2: 420-430.
19. Chen G, Goeddel DV. TNF-RI signaling: a beautiful pathway. Science 2002; 296: 1634-1635.
20. Hussein MR, Haemel AK, Wood GS. Apoptosis and melanoma: molecular mechanisms. J Pathol 2003; 199: 275-288.
21. Walezak H, Miller RE, Ariali K, et al. Tumoricidal activity of tumour-necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 1999; 5: 157-163.
22. Teicher BA. Malignant cells, directors of the malignant process: role of transforming growth factor-beta. Cancer Metastasis Rev 2001; 20: 133-143.
23. Thomas GJ, Hart IR, Speight PM, et al. Binding of TGF-beta1 latency-associated peptide (LAP) to alpha(v)beta6 integrin modulates behaviour of squamous carcinoma cells. Br J Cancer 2002; 87: 859-867.
24. Kelly-Welch AE, Hanson EM, Boothby MR, et al. Interleukin-4 and interleukin-13 signaling connections maps. Science 2003; 300: 1527-1528.
25. Anasagasti MJ, Olaso E, Calvo F, et al. Interleukin 1-dependent and -independent mouse melanoma metastases. J Natl Cancer Inst 1997; 89: 645-651.
26. Mansoor A, Hoosein N. Relationship of the interleukin-1 system with neuroendocrine and exocrine markers in human colon cancer cell lines. Cytokine 2002; 18: 86-91.
27. Brew R, Erikson JS, West DC, et al. Interleukin-8 as an autocrine growth factor for human colon carcinoma cells in vitro. Cytokine 2000; 12: 78-85.
28. Boneechi R, Facchetti F, Dusi S, et al. Induction of functional IL-8 receptors by IL-4 and IL-13 in human monocytes. J Immunol 20001; 164: 3862-3869.
29. Kwak JY, Han MK, Chaoi KS, et al. Cytokines secreted by lymphokine-activated killer cells induce endogenous nitric oxide synthesis and apoptosis in DLD-1 colon cancer cells. Cell Immunol 2000; 203: 84-94. Cell Immunol 2000; 203: 84-94.
30. Pellegrini P, Berghella AM, Del Beato T, et al. Disregulation in TH1 and TH2 subsets of CD4+ T cells in peripheral blood of colorectal cancer patients and involvement in cancer establishment and progression. Cancer Immunol Immunother 1996; 42: 1-8.
31. Wang YQ, Ugai S, Shimozato O, et al. Induction of systemic immunity by expression of interleukin-23 in murine colon carcinoma cells. Int J Cancer 2003; 105: 820-824.
32. Luo JS, Kammerer R, Schultze H, et al. Modulations of the effector function and cytokine production of human lymphocytes by secreted factors derived from colorectal-carcinoma cells. Int J Cancer 1997; 72: 142-148.
33. Komberg LJ. Focal adhesion kinase and its potential involvement in tumor invasion and metastasis. Head Neck 1998; 20: 745-752.
34. Hague A, Hicks DJ, Bracey TS, et al. Cell-cell contact and specific cytokines inhibit apoptosis of colonic epithelial cells: growth factors protect against c-myc-independent apoptosis. Br J Cancer 1997; 75: 960-968.
35. Sun FF, Lai PS, Yue G, et al. Pattern of cytokine and adhesion molecule mRNA in hapten-induced relapsing colon inflammation in the rat. Inflammation 2001; 25: 33-45.
36. Melero I, Gabari I, Corbi AL, et al. An anti-ICAM-2 (CD102) monoclonal antibody induces immune-mediated regressions of transplanted ICAM-2-negative colon carcinomas. Cancer Res 2002; 62: 3167-3174.
37. Avizienyte E, Wyke AW, Jones RJ, et al. Src-induced deregulation of E-cadherin in colon cancer cells requires integrin signalling. Nat Cell Biol 2002; 4: 632-638.
38. Kanai T, Watanabe M, Hayashi A, et al. Regulatory effect of interleukin-4 and interleukin-13 on colon cancer cell adhesion. Br J Cancer 2000; 82: 1717-1723.
39. Reed JC. Mechanisms of apoptosis. Am J Pathol 2000; 157: 1415-1430.
40. Osaki M, Kase S, Kodani I, et al. Expression of Fas and Fas ligand in human gastric adenomas and intestinal-type carcinomas: correlation with proliferation and apoptosis. Gastric Cancer 2001; 4: 198-205.
41. Belluco C, Esposito G, Bertorelle R, et al. Fas ligand is upregulated during the colorectal adenoma-carcinoma sequence. Eur J Surg Oncol 2002; 28: 120-125.
42. Herbcuval JP, Lambert C, Sabido O, et al. Macrophages from cancer patients: analysis of TRAIL, TRAIL receptors, and colon tumor cell apoptosis. J Natl Cancer Inst 2003; 95: 611-621.
43. Dong M, Guda K, Nambiar PR, et al. Inverse association between phospholipase A2 and COX-2 expression during mouse colon tumorigenesis. Carcinogenesis 2003; 24: 307-315.
44. Shibata M, Takekawa M, Amano S. Increased serum concentrations of soluble tumor necrosis factor receptor I in noneachectic and cachectic patients with advanced gastric and colorectal cancer. Surg Today 1998; 28: 884-888.
45. Iwagaki H, Yagi T, Urushihara N, et al. Blood transfusion and postoperative plasma cytokine antagonist levels in colorectal cancer patients. Hepatogastroenterology 2001; 48: 1351-1354.
46. Fink SP, Swinler SE, Lutterbaugh JD, et al. Transforming growth factor-beta-induced growth inhibition in a Smad4 mutant colon adenoma cell line. Cancer Res 2001; 61: 256-260.
47. Torbenson M, Marinopoulos S, Dang DT, et al. Smad4 overexpression in hepatocellular carcinoma is strongly associated with transforming growth factor beta II receptor immunolabeling. Hum Pathol 2002; 33: 871-876.
48. Guda K, Giardina C, Nambiar P, et al. Aberrant transforming growth factor-beta signaling in azoxymethane-induced mouse colon tumors. Mol Carcinog 2001; 31: 204-213
49. Matsushita M, Matsuzaki K, Date M, et al. Down-regulation of TGF-beta receptors in human colorectal cancer: implications for cancer development. Br J Cancer 1999; 80: 194-205.
50. Kushiyama Y, Fukuda R, Suetsugu H, et al. Site-dependent production of transforming growth factor beta1 in colonic mucosa: its possible role in tumorigenesis of the colon. J Lab Clin Med 2000; 136: 201-208.
51. Dimberg J, Hugander A, Sirsjo A. Decreased levels of precursor transforming growth factor beta1 in human colorectal cancer. Int J Mol Med 2001; 7: 597-601
52. Strassmann G, Fong M, Windsor S, et al. The role of interleukin-6 in lipopolysaccharide-induced weight loss, hypoglycemia and fibrinogen production, in vivo. Cytokine 1993; 5: 285-290.
53. Kojima M, Morisaki T, Izuhara K, et al. Lipopolysaccharide increases cyclo-oygenase-2 expression in a colon carcinoma cell line through nuclear factor-kappa B activation. Oncogene 2000; 19: 1225-1231.
54. McKelvey W, Greenland S, Sandler RS. A second look at the relation between colorectal adenomas and consumption of foods containing partially hydrogenated oils. Epidemiology 2000; 11: 469-473.
55. Erhardt JG, Kreichgauer HP, Meisner C, et al. Alcohol, cigarette smoking, dietary factors and the risk of colorectal adenomas and hyperplastic polyps-a case control study. Eur J Nutr 2002; 41: 35-43.
56. Mutanen M, Pajari AM, Oikarinen SI. Beef induces and rye bran prevents the formation of intestinal polyps in Apc(Min) mice: relation to beta-catenin and PKC isozymes. Carcinogenesis 2000; 21: 1167-1173.
57. Sandhu MS, Dunger DB, Giovannucci EL. Insulin, insulin-like growth factor-I (IGF-I), IGF binding proteins, their biologic interactions, and colorectal cancer. J Natl Cancer Inst 2002; 94: 972-980.
58. Reinmuth N, Liu W, Fan F, et al. Blockade of insulin-like growth factor I receptor function inhibits growth and angiogenesis of colon cancer. Clin Cancer Res 2002; 8: 3259-3269.
59. Giovannucci E. Insulin, insulin-like growth factors and colon cancer: a review of the evidence. J Nutr 2001; 131: 3109S-3120S.
60. Remacle-Bonnet MM, Garrouste FL, Heller S, et al. Insulin-like growth factor-I protects colon cancer cells from death factor-induced apoptosis by potentiating tumor necrosis factor alpha-induced mitogen-activated protein kinase and nuclear factor kappaB signaling pathways. Cancer Res 2000; 60: 2007-2017.